AOD-9604 in Medraz — Fat Loss Peptide Research Guide
AOD-9604 research guide for Medraz. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
For anyone in Medraz searching for AOD-9604, the first thing to know is that this compound is available only through an online research supply market. The key implication for Medraz researchers: sourcing AOD-9604 hinges on vendor quality evaluation, not geography — and the quality verification approach is identical for researchers everywhere. Separating quality AOD-9604 from the rest of the market comes down to three things: an HPLC chromatogram documenting ≥98% purity, mass spec data verifying the correct molecular weight, and a batch-specific endotoxin panel. Use this guide to evaluate AOD-9604 vendors rigorously — the standards covered in this guide work regardless of your location.
Understanding AOD-9604 — Biology & Evidence
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Medraz researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
How to Evaluate AOD-9604 Vendors
Vetting AOD-9604 vendors begins with the COA: access the batch-specific certificate before placing an order, not after. A COA for AOD-9604 should include: HPLC purity percentage with the actual chromatogram data, mass spectrometry data confirming the correct molecular weight, endotoxin test results, and a residual solvent panel — all specific to the lot you receive. Strong quality indicators beyond COA quality: multi-year operating history, knowledgeable support capable of explaining COA data, and shipping with desiccant and appropriate cold protection. Price is an ineffective primary criterion for AOD-9604 quality — research-grade synthesis and testing has genuine production costs that cannot be cut without consequences, so significantly below-market pricing signals compromises.
Order AOD-9604 — ships to Medraz
COA-verified · International tracking · Research grade
As a research compound, AOD-9604 has not undergone the clinical trial process required for pharmaceutical approval — its safety profile is defined by animal study data and small-scale human observations. Storage requirements for AOD-9604: lyophilised powder at minus 20°C, reconstituted solution stored refrigerated at 2-8°C and finished within 30 days of reconstitution; reconstitute only with sterile bacteriostatic water. Quality AOD-9604 sourcing directly determines safety outcomes — bacterial endotoxin contamination, wrong peptide identity, and degraded material are all safety issues that proper COA verification addresses. Protocol documentation — documenting product details, dates, and administration precisely — is a sound practice for any AOD-9604 protocol that allows any unexpected observations to be properly contextualised.
Frequently Asked Questions
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
